The Family Smoking Prevention and Control Act (Tobacco Control Act or TCA) of 2009 and the subsequent Deeming Rule of 2016 gave the United States (U.S.) Food and Drug Administration (FDA) the authority to regulate all tobacco products and nicotine derived tobacco products to protect the public health and reduce tobacco use by minors. Deemed tobacco products are e-cigarettes and other electronic nicotine delivery systems (ENDS), cigars, pipe and hookah tobacco, nicotine gel, and dissolvable nicotine products. The Consolidated Appropriations Act of 2022, further extended the jurisdiction of the FDA and application of the TCA to all products containing nicotine from any source.
All tobacco products must be approved for marketing in the U.S. by the FDA. Tobacco products may be:
Section 902 and 906(e)(1) of the Food, Drug, and Cosmetic Act (FDCA), which was added with the passage of the TCA, states that a tobacco product is considered adulterated if the methods used in, and the facilities and controls used for, the manufacture, preproduction design validation (including a process to assess the performance of a tobacco product), packing, and storage of a tobacco product do not conform to Current Good Manufacturing Practices (cGMPs).
Tobacco product cGMPs are referred to as Tobacco Product Manufacturing Practices (TPMPs). The proposed TPMPs were published in the Federal Register with the Notice of Proposed RuleMaking (NPRM) on March 10, 2023. An “umbrella” approach to 21 CFR 1120 for all types of finished and bulk tobacco products was employed by the FDA for these proposed TPMPs. This is similar to the approach taken by the other codified cGMPs and voluntary standards, such as FDA Guidance for Industry. The proposed TPMPs are a foundational rule for tobacco product regulation by the FDA Center for Tobacco Products (CTP) https://www.fda.gov/tobacco-products.
A cGMP quality management system (QMS) must be in place for compliance with the proposed TPMPs. The QMS is the formal, documented system that dictates all controlled processes and procedures to obtain and consistently maintain product quality and regulatory compliance. This cGMP QMS will be assessed upon an FDA on-site inspection, Remote Regulatory Assessment (RRA), Remote Interactive Evaluation (RIE), or Pre-Approval Inspection (PAI) for new tobacco products.
TLC Regulatory and Laboratory Consulting can provide assistance to clients with the development, improvement, and implementation of a cGMP QMS, and all preparation efforts for an FDA assessment and communications thereof.